This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

4 Biotech Stocks Under $10 Moving Higher

Peregrine Pharmaceuticals

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Peregrine Pharmaceuticals (PPHM - Get Report) is a clinical-stage biopharmaceutical company that develops and manufactures monoclonal antibodies for the treatment of cancer and viral infections. This stock is trading up 22.2% to 89 cents per share in recent trading.

Today's Range: $0.76-$0.94

52-Week Range: $0.39-$2.26

Volume: 2.2 million

Three-Month Average Volume: 875,371

Shares of PPHM are skyrocketing today in front of its quarterly earnings report, which is due out on July 16 after the market close.

>>Hot Biotech Stocks Traded by Hedge Funds

From a technical perspective, PPHM is soaring back above its 200-day moving average of 79 cents with heavy volume, and it's broken out above some near-term overhead resistance at 78 cents. If this momentum buying can continue, then PPHM could manage to trigger more near-term breakout moves. Those breakouts will hit once PPHM takes out $1.01 to $1.14 with high volume.

Traders should now look for long-biased trades in PPHM as long as it's trending above its 200-day at 79 cents, and near its daily highs with strong upside volume flows. I would consider any upside volume day that registers near or above 875,371 shares as bullish. If we continue to see that action, then PPHM could take out $1.01 to $1.14 prior to its earnings report. On the flipside, I would avoid this stock if it moves back below 79 cents with heavy volume.

2 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ANX $0.73 0.00%
OREX $7.54 0.00%
PPHM $1.38 0.00%
SQNM $3.90 0.00%
AAPL $123.25 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs